High-resolution DNA size enrichment using a magnetic nano-platform and application in non-invasive prenatal testing

Non-invasive prenatal testing (NIPT) using cell-free fetal DNA (cffDNA) from maternal blood has recently entered clinical practice in many countries, including Canada. This test can be performed early during pregnancy to detect Down syndrome and other conditions. While NIPT promises numerous benefits, it also has challenging ethical, legal and social implications (ELSI). This paper reviews concerns currently found in the literature on the ELSI of NIPT. We make four observations. First, NIPT seems to exacerbate some of the already existing concerns raised by other prenatal tests (amniocentesis and maternal serum screening) such as threats to women’s reproductive autonomy and the potential for discrimination and stigmatization of disabled individuals and their families. This may be due to the likely upcoming large scale implementation and routinization of NIPT. Second, the distinction between NIPT as a screening test (as it is currently recommended) and as a diagnostic test (potentially in the future), has certain implications for the ELSI discussion. Third, we observed a progressive shift in the literature from initially including mostly conceptual analysis to an increasing number of empirical studies. This demonstrates the contribution of empirical bioethics approaches as the technology is being implemented into clinical use. Finally, we noted an increasing interest in equity and justice concerns regarding access to NIPT as it becomes more widely implemented.

Download Full-text

Non-Invasive Prenatal Testing: Current Perspectives and Future Challenges

Genes ◽

10.3390/genes12010015 ◽

2020 ◽

Vol 12 (1) ◽

pp. 15

Author(s):

Luigi Carbone ◽

Federica Cariati ◽

Laura Sarno ◽

Alessandro Conforti ◽

Francesca Bagnulo ◽

...

Keyword(s):

Prenatal Screening ◽

Prenatal Testing ◽

Non Invasive ◽

Fetal Dna ◽

Cell Free Fetal Dna ◽

Common Causes ◽

Future Challenges ◽

Neurodevelopmental Impairment ◽

Fetal Aneuploidies ◽

Made In

Fetal aneuploidies are among the most common causes of miscarriages, perinatal mortality and neurodevelopmental impairment. During the last 70 years, many efforts have been made in order to improve prenatal diagnosis and prenatal screening of these conditions. Recently, the use of cell-free fetal DNA (cff-DNA) testing has been increasingly used in different countries, representing an opportunity for non-invasive prenatal screening of pregnant women. The aim of this narrative review is to describe the state of the art and the main strengths and limitations of this test for prenatal screening of fetal aneuploidies.

Download Full-text

Non-Invasive Testing, Non-Invasive Counseling

The Journal of Law Medicine & Ethics ◽

10.1111/jlme.12237 ◽

2015 ◽

Vol 43 (2) ◽

pp. 228-240 ◽

Cited By ~ 2

Author(s):

Rachel Rebouché

Keyword(s):

Chromosomal Abnormalities ◽

Genetic Test ◽

Prenatal Testing ◽

Private Companies ◽

Major Health ◽

Prenatal Health ◽

Non Invasive ◽

Fetal Dna ◽

Cell Free Fetal Dna ◽

A Company

A regulatory moment for prenatal health care is here. An increasing amount of legislative attention has concentrated on the decisions pregnant women make after prenatal testing. The impetus for this legislation is a new non-invasive prenatal genetic test (NIPT). From the beginning of pregnancy, cell-free fetal DNA travels across the placental lining into the mother’s bloodstream, increasing in quantity as the pregnancy progresses. Laboratories can now analyze that DNA for chromosomal abnormalities and for fetal sex at 10 weeks of gestation. NIPT, which relies on a sample of the pregnant woman’s blood, is painless, occurs early in pregnancy, and is available for clinical and commercial use. In 2013, major health insurance plans began to cover NIPT for certain populations of women, such as women over 35 years old. And private companies have started marketing prenatal testing kits directly to consumers, who return a blood sample from the prospective mother to a company laboratory.

Download Full-text

Cell‐free fetal DNA and fetal blood group genotyping: non‐invasive prenatal testing

ISBT Science Series ◽

10.1111/voxs.12521 ◽

2019 ◽

Vol 15 (1) ◽

pp. 46-51 ◽

Cited By ~ 2

Author(s):

Frederik Banch Clausen

Keyword(s):

Blood Group ◽

Prenatal Testing ◽

Fetal Blood ◽

Non Invasive ◽

Fetal Dna ◽

Cell Free Fetal Dna

Download Full-text

1.1 Non-Invasive Prenatal Testing Using Cell Free Fetal DNA in Maternal Plasma: An Aid to Prenatal Sonographic Diagnosis: Abstract 1.1 Table

Archives of Disease in Childhood - Fetal and Neonatal Edition ◽

10.1136/archdischild-2013-303966.001 ◽

2013 ◽

Vol 98 (Suppl 1) ◽

pp. A1.1-A1

Author(s):

LS Chitty ◽

A Barrett ◽

F Mackay ◽

S Fielding ◽

N Lench

Keyword(s):

Prenatal Testing ◽

Maternal Plasma ◽

Sonographic Diagnosis ◽

Non Invasive ◽

Fetal Dna ◽

Cell Free Fetal Dna

Download Full-text

Cell-free fetal DNA and intact fetal cells in maternal blood circulation: implications for first and second trimester non-invasive prenatal diagnosis

Human Reproduction Update ◽

10.1093/humupd/8.6.493 ◽

2002 ◽

Vol 8 (6) ◽

pp. 493-500 ◽

Cited By ~ 45

Author(s):

F. Z. Bischoff

Keyword(s):

Prenatal Diagnosis ◽

Blood Circulation ◽

Maternal Blood ◽

Second Trimester ◽

Fetal Cells ◽

Non Invasive ◽

Fetal Dna ◽

Cell Free Fetal Dna

Download Full-text

Correction: High-resolution DNA size enrichment using a magnetic nano-platform and application in non-invasive prenatal testing

The Analyst ◽

10.1039/d1an90111g ◽

2022 ◽

Author(s):

Bo Zhang ◽

Shuting Zhao ◽

Hao Wan ◽

Ying Liu ◽

Fei Zhang ◽

...

Keyword(s):

High Resolution ◽

Prenatal Testing ◽

Non Invasive ◽

Dna Size

Correction for ‘High-resolution DNA size enrichment using a magnetic nano-platform and application in non-invasive prenatal testing’ by Bo Zhang et al., Analyst, 2020, 145, 5733–5739, DOI: 10.1039/D0AN00813C.

Download Full-text